Meng HJ, Mao Y, Zhao DQ, Shi SG. Prognostic value of the triglyceride-glucose index in advanced gastric cancer: A call for further exploration. World J Gastroenterol 2025; 31(15): 104574 [DOI: 10.3748/wjg.v31.i15.104574]
Corresponding Author of This Article
Hong-Jie Meng, MD, Associate Chief Physician, Senior Researcher, Department of Gastrointestinal Surgery Ward, Zhuji People’s Hospital, No. 9 Jianmin Road, Taozhu Street, Zhuji 311800, Zhejiang Province, China. mhj7768@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 21, 2025; 31(15): 104574 Published online Apr 21, 2025. doi: 10.3748/wjg.v31.i15.104574
Prognostic value of the triglyceride-glucose index in advanced gastric cancer: A call for further exploration
Hong-Jie Meng, Yi Mao, De-Qing Zhao, Sheng-Guang Shi
Hong-Jie Meng, Yi Mao, De-Qing Zhao, Sheng-Guang Shi, Department of Gastrointestinal Surgery Ward, Zhuji People’s Hospital, Zhuji 311800, Zhejiang Province, China
Author contributions: Meng HJ conceptualization, writing, reviewing and editing; Mao Y methodology and formal analysis; Zhao DQ and Shi SG supervision and writing of the original draft; Meng HJ, Mao Y, Zhao DQ, and Shi SG participated in drafting the manuscript and have read it, and all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Jie Meng, MD, Associate Chief Physician, Senior Researcher, Department of Gastrointestinal Surgery Ward, Zhuji People’s Hospital, No. 9 Jianmin Road, Taozhu Street, Zhuji 311800, Zhejiang Province, China. mhj7768@163.com
Received: December 25, 2024 Revised: March 9, 2025 Accepted: March 17, 2025 Published online: April 21, 2025 Processing time: 114 Days and 22.5 Hours
Abstract
Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, necessitating the identification of reliable prognostic indicators to enhance treatment outcomes. Recent research has highlighted the triglyceride-glucose (TyG) index as a potential surrogate marker for insulin resistance, which may significantly influence the prognosis of patients undergoing immunotherapy combined with chemotherapy. In this context, the study by Yao et al demonstrates that a high TyG index correlates with improved overall survival and progression-free survival in advanced GC patients receiving sintilimab and chemotherapy. Specifically, patients in the high TyG group had a significantly longer median progression-free survival of 9.8 months [95% confidence interval (CI): 9.2-10.9] compared to 8.0 months (95%CI: 7.5-8.5) in the low TyG group (hazard ratio = 0.58, 95%CI: 0.43-0.79, P < 0.001). Similarly, the median overall survival was significantly longer in the high TyG group at 23.1 months (95%CI: 21.2-NA) vs 16.5 months (95%CI: 13.9-18.3) in the low TyG group (hazard ratio = 0.30, 95%CI: 0.21-0.42, P < 0.001). These findings underscore the strong prognostic potential of the TyG index in guiding treatment strategies for advanced GC. These findings underscore the need for further investigation into the TyG index’s role as a prognostic tool and its underlying mechanisms in influencing treatment efficacy. We advocate for additional multicenter studies to validate these results and explore the TyG index’s applicability across diverse patient populations, ultimately aiming to refine treatment strategies and improve patient outcomes in advanced GC.
Core Tip: The triglyceride-glucose (TyG) index, a surrogate marker for insulin resistance, has emerged as a potential prognostic factor in advanced gastric cancer. Recent findings suggest that a high TyG index correlates with improved overall survival and progression-free survival in patients undergoing immunotherapy combined with chemotherapy. This highlights the clinical relevance of insulin sensitivity in modulating treatment efficacy. Further multicenter studies are essential to validate its prognostic value across diverse populations and to explore underlying mechanisms. Integrating the TyG index into comprehensive prognostic models may optimize treatment strategies and improve patient outcomes in advanced gastric cancer.
